D-dimer as a potential biomarker in chronic obstructive pulmonary disease
DOI:
https://doi.org/10.15584/ejcem.2025.2.20Keywords:
chronic obstructive pulmonary disease, D-dimer, inflammatory markers, smoking, spirometryAbstract
Introduction and aim. Despite signs of drop in tuberculosis in the middle of the twentieth century, up to 75% of men were smokers at that time, which contributed to the epidemic of chronic obstructive pulmonary disease (COPD) in the latter half of the century. The present study was conducted with the main focus of establishing a relation between D-dimer and lung function in patients with COPD.
Material and methods. A hospital-based observational cross-sectional study involved 108 subjects, divided into 54 cases (COPD patients) and 54 healthy controls (41-80 years old). The dry volume spirometer was used to assess the lung health of the study population. D-dimer assay was performed on peripheral blood drawn from study subjects using the second generation latex-enhanced immunoturbidimetric assay on the Diagon Fully Automatic COAG XL Coagulation Analyzer.
Results. Spirometry tests revealed COPD patients showing reduced lung function (42.59% with normal, 51.85% with mild, and 5.56% with moderate degree of forced expiratory volume in 1 second and forced expiratory volume in 1 second/ forced vital capacity). Patients with COPD under different age groups and both the genders showed an elevated level (p<0.05) of D-dimer in correlation with the spirometry measurements.
Conclusion. The D-dimer is promising plasma biomarker which demonstrated a strong correlation with the spirometry measurements and different morphological categories in patients with COPD. The D-dimer could serve as a reliable biomarker for validating and confirming the various morphological classifications among individuals with COPD.
Downloads
References
Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11(3):404-406. doi: 10.1513/AnnalsATS.201311-405PS
Hansel TT, Barnes PJ. An Atlas of Chronic Obstructive Pulmonary Disease (1st ed.). CRC Press. 2003. doi: 10.3109/9780203490723
López‐Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14-23. doi: 10.1111/resp.12660
Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264-272. doi: 10.1183/09031936.00051110
Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151-1156. doi: 10.1164/ajrccm/147.5.1151
Daga MK, Mahapatra SJ, Prakash SK, Gupta N. The Study Of Prothrombotic Markers In Patients With Chronic Obstructive Pulmonary Disease And Its Correlation With Acute Exacerbation.” D41. COPD: BIOMARKERS IN STABLE DISEASE AND EXACERBATIONS. American Thoracic Society. 2014;A5899-A5899.
Hanania NA, Mullerova H, Locantore N, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183:604-611. doi: 10.1164/rccm.201003-0472OC
Sin DD. Asthma-COPD Overlap Syndrome: What We Know and What We Don’t. Tuberc Respir Dis (Seoul). 2017;80:11-20. doi: 10.4046/trd.2017.80.1.11
Norbäck D, Zock JP, Plana E, et al. Lung function decline in relation to mould and dampness in the home: the longitudinal European Community Respiratory Health Survey ECRHS II. Thorax. 2011;66(5):396-401. doi: 10.1136/thx.2010.146613
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70-88. doi: 10.1164/rccm.201908-1590ST
Silveyra P, Fuentes N, Rodriguez Bauza DE. Sex and gender differences in lung disease. InLung Inflammation in Health and Disease, Volume II 2021 May 22. Cham: Springer International Publishing. 2021:227-258.
Eich A, Urban V, Jutel M, et al. A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease. COPD. 2017,14(5):476-483. doi: 10.1080/15412555.2017.1335697
Akpinar EE, Hoşgün D, Doğanay B, Ataç GK, Gülhan M. Should the cut-off value of D-dimer be elevated to exclude pulmonary embolism in acute exacerbation of COPD?. J Thorac Dis. 2013;5(4):430-434. doi: 10.3978/j.issn.2072-1439.2013.07.34
Manon-Jensen T, Langholm LL, Rønnow SR, et al. End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. Respir Med. 2019;160:105814. doi: 10.1016/j.rmed.2019.105814
Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555. doi: 10.1164/rccm.200703-456SO
Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204-212. doi: 10.1183/09031936.00114307
Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66(9):769-774. doi: 10.1136/thx.2010.157529
Arregui MA, Ezquerra KL, López FC, Lacasa RC. Hypercoagulability state and endotelial injury in stable chronic obstructive pulmonary disease patients. An Sist Sanit Navar. 2010;33(1):43-50.
Kattainen S, Pitkänen H, Reijula J, Hästbacka J. Complete blood count, coagulation biomarkers, and lung function 6 months after critical COVID‐19. Acta Anaesthesiol Scand. 2024;68(7):940-948. doi: 10.1111/aas.14437
Baidya A, Sangle S, Marbaniang I, et al. Clinical and immunological markers of pulmonary impairment among people with HIV in India. InOpen Forum Infectious Diseases 2022 Jul 1 (Vol. 9, No. 7, p. ofac233). Oxford University Press.
GOLD (Global Initiative for Chronic Obstructive Pulmonary Disease). 2015. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. http://goldcopd.org/. Accessed November 8, 2024.
Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015;349(1):29-35. doi: 10.1097/MAJ.0000000000000332
Sadeghi S, Emami Ardestani M, Raofi E, Jalaie Esfandaba di A. Diagnostic Value of D-dimer in Detecting Pulmonary Embolism in Patients with Acute COPD Exacerbation. Tanaffos. 2020;19(4):371-379.
Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8:49. doi: 10.1186/s40560-020-00466-z
Saymaz ZT, Çelik D, Yıldız M, Ertan Ö. The effects of D-dimer high rates on prognosis and mortality in chronic obstructive respiratory disease. Anatolian Current Medical Journal. 2022;4(1):44-50. doi: 10.38053/acmj.1023590
NICE (National Institute for Health and Care Excellence). 2010. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Guideline CG101. https://www.nice.org.uk/guidance/cg101. Accessed November 8, 2024.
Verma A, Gudi N, Yadav UN, et al. Prevalence of COPD among population above 30 years in India: A systematic review and meta-analysis. Journal of Global Health. 2021;11:04038. doi: 10.7189/jogh.11.04038
Baqdunes MW, Leap J, Young M, Kaura A, Cheema T. Acute exacerbation of chronic obstructive pulmonary disease. Critical Care Nursing Quarterly. 2021;44(1):74-90. doi: 10.1097/CNQ.0000000000000341
Amin N. An overview of COPD, causes, clinical manifestations, complications and its management. J Nurs Sci Pract Res Adv. 2023;5(1):33-40.
Claxton S, Porter P, Brisbane J, et al. Identifying acute exacerbations of chronic obstructive pulmonary disease using patient-reported symptoms and cough feature analysis. NPJ Digital Medicine. 2021;4(1):107. doi: 10.1038/s41746-021-00472-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
